X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC LTD SUN PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 32.5 51.1 63.6% View Chart
P/BV x 2.5 2.2 115.2% View Chart
Dividend Yield % 0.5 0.5 107.5%  

Financials

 SUN PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ALEMBIC LTD
Mar-18
SUN PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs70172 972.9%   
Low Rs43334 1,277.9%   
Sales per share (Unadj.) Rs110.44.7 2,348.8%  
Earnings per share (Unadj.) Rs11.06.1 179.9%  
Cash flow per share (Unadj.) Rs17.26.2 275.9%  
Dividends per share (Unadj.) Rs2.000.20 1,000.0%  
Dividend yield (eoy) %0.40.4 93.4%  
Book value per share (Unadj.) Rs158.840.7 390.5%  
Shares outstanding (eoy) m2,399.26267.03 898.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.111.3 45.6%   
Avg P/E ratio x51.68.7 595.2%  
P/CF ratio (eoy) x32.98.5 388.1%  
Price / Book Value ratio x3.61.3 274.1%  
Dividend payout %18.23.3 556.0%   
Avg Mkt Cap Rs m1,360,02114,139 9,618.8%   
No. of employees `00017.8NA-   
Total wages/salary Rs m53,671207 25,877.8%   
Avg. sales/employee Rs Th14,890.9NM-  
Avg. wages/employee Rs Th3,017.1NM-  
Avg. net profit/employee Rs Th1,480.6NM-  
INCOME DATA
Net Sales Rs m264,8951,255 21,103.8%  
Other income Rs m8,388370 2,265.7%   
Total revenues Rs m273,2821,625 16,813.2%   
Gross profit Rs m56,081111 50,478.2%  
Depreciation Rs m14,99838 39,678.3%   
Interest Rs m5,1762 304,452.9%   
Profit before tax Rs m44,295442 10,026.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,45224 35,289.8%   
Profit after tax Rs m26,3381,630 1,616.0%  
Gross profit margin %21.28.9 239.2%  
Effective tax rate %19.15.4 352.0%   
Net profit margin %9.9129.8 7.7%  
BALANCE SHEET DATA
Current assets Rs m316,3591,867 16,943.9%   
Current liabilities Rs m198,643591 33,600.0%   
Net working cap to sales %44.4101.6 43.7%  
Current ratio x1.63.2 50.4%  
Inventory Days Days9594 100.6%  
Debtors Days Days10874 146.4%  
Net fixed assets Rs m213,1781,791 11,903.4%   
Share capital Rs m2,399534 449.2%   
"Free" reserves Rs m378,60610,324 3,667.4%   
Net worth Rs m381,00610,858 3,509.1%   
Long term debt Rs m17,72141 43,011.9%   
Total assets Rs m643,02811,591 5,547.9%  
Interest coverage x9.6260.9 3.7%   
Debt to equity ratio x00 1,225.7%  
Sales to assets ratio x0.40.1 380.4%   
Return on assets %4.914.1 34.8%  
Return on equity %6.915.0 46.1%  
Return on capital %10.015.2 66.0%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m40,81619 210,393.8%   
Fx outflow Rs m30,143264 11,425.7%   
Net fx Rs m10,673-244 -4,366.7%   
CASH FLOW
From Operations Rs m39,072236 16,569.8%  
From Investments Rs m-33,708-224 15,048.3%  
From Financial Activity Rs m-15,393-27 57,866.9%  
Net Cashflow Rs m-7,359-15 49,723.6%  

Share Holding

Indian Promoters % 63.7 64.0 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.2 2,565.0%  
FIIs % 23.0 9.7 237.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 26.1 31.8%  
Shareholders   133,026 54,701 243.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  WYETH LTD  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 10, 2018 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - BIOCON LTD COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS